Gacovino Lake

Personal Injury Attorneys

Call Today For A FREE Consultation
(631) 600-0000
  • Home
  • About Us
    • Areas We Serve
  • Practice Areas
    • Dangerous Drugs
    • Defective Medical Devices
    • Offshore Injury Lawyer
    • Medical Malpractice
    • Vehicle Accidents
    • Another’s Property
    • All Other Cases
  • Attorneys
  • News
    • FDA Safety Info – Drugs & Medical Devices
  • Resources
    • Frequently Asked Questions
  • Contact Us
You are here: Home / News / FDA Approves Breast Cancer Medicine

June 9, 2012 By: galadmin

FDA Approves Breast Cancer Medicine

(June 9, 2012) The U.S. Food and Drug Administration (FDA) approved a new anti-HER2 therapy, called Perjeta (pertuzumab) to treat patients with HER2-positive late-stage (metastatic) breast cancer.  Perjeta is combined with trastuzumab, another anti-HER2 therapy, and docetaxel, a type of chemotherapy.

HER2 is a protein involved in normal cell growth, and is found in increased amounts on some types of cancer cells (HER2-positive), including some breast cancers. The increased amount of HER2 protein in these HER2-positive breast cancers contributes to cancer cell growth., as well as survival.

Perjeta is intended for patients who have not received prior treatment for metastatic breast cancer with an anti-HER2 therapy or chemotherapy.

Perjeta is administered through an IV, and is a humanized monoclonal antibody, manufactured through biotechnology methods.

Currently, breast cancer is the second leading cause of cancer-related death among women. In fact, an estimated 226,870 women will be diagnosed this year, and 39,510 will die from the disease.

Janet Woodcock, M.D., director of FDA’s Center for Drug Evaluation and Research, said,  “given the need for additional treatments for metastatic breast cancer, we made the decision to approve this drug today and not to delay its availability to patients pending resolution of the production issues relating to future supply.”

Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug and Research, said, “since trastuzumab was first approved more than a decade ago, continued research has allowed us to better understand the role HER2 plays in breast cancer. This research provided the background to combine two targeted drugs – trastuzuman and Perjeta with docetaxel to slow disease progression in breast cancer.”

In a study designed to measure the length of time a patient lived without the cancer progressing, progession-free survival (PFS), those treated with the combination containing Perjeta had a median PFS of 18.5 months, whereas those treated with the combination containing placebo had a median PFS of 12.4.

Common side effects are diarrhea, hair loss,  a decrease in infection-fighting white blood cells, nausea, fatigue, rash, and nerve damage.

Share
« Smoking Hookah May Be More Harmful Than Smoking Cigarettes
Packaging Flaw Leads to Recall of Contraceptives »

Free Case Review

You Be The Judge

Introducing our new online series You Be the Judge where we take you in to pull back the curtain, investigate the facts, and let you draw your own conclusions.

Talcum Powder Linked to Cancer

Several studies — and the anecdotal evidence from thousands of women across the country — link the use of talcum powder on or near the genitals with ovarian cancer. This correlation is strong enough that juries across ... continue reading...

  • Home
  • About Us
    • Areas We Serve
  • Practice Areas
    • Dangerous Drugs
    • Defective Medical Devices
    • Offshore Injury Lawyer
    • Medical Malpractice
    • Vehicle Accidents
    • Another’s Property
    • All Other Cases
  • Attorneys
  • News
    • FDA Safety Info – Drugs & Medical Devices
  • Resources
    • Frequently Asked Questions
  • Contact Us

Contact Our Firm

Gacovino, Lake & Associates, P.C.
270 W Main St
Sayville, NY 11782

Phone: +1 (800) 550-0000
Phone: +1 (631) 600-0000
Fax: (631) 543-5450


 

 
Attorney Advertising Legal Disclaimer – Admitted in NY, NJ, CT, and Washington, D.C. only. While this firm maintains joint responsibility, your case may be referred to local or trial counsel for primary handling. Not available in all states. Prior results cannot and do not guarantee or predict a similar outcome with respect to any future matter, including yours, in which a lawyer or law firm may be retained.
Site Map
Gacovino Lake & Associates, P.C. | All Rights Reserved